Form 4 for ARWR ARROWHEAD PHARMACEUTICALS, INC.
Accepted 2021-12-23 00:00:00 ET · period of report 2021-12-23 · accession 0001209191-21-071196 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-12-23 | 2021-12-23 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $5.19 | +11.8K | 3.25M | +0.4% | +$61.3K |
| D | 2021-12-23 | 2021-12-23 | ARWR | Anzalone Christopher Richard | CEO, Dir | M - OptEx | $0.00 | -11.8K | 773.2K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-12-23 | M | A | 11,806 | $5.19 | 3,245,828 | D | — | — | (F1) Includes a total of 1,400,000 shares underlying restricted stock units that may be earned based on the achievement of certain performance goals. If the performance goals are not met within the required time periods, the awards will be forfeited in part or in whole |
| 2 | Derivative | Stock Option (right to buy Common Stock) | 2021-12-23 | M | D | 11,806 | $0.00 | 773,227 | D | $5.19 · 2012-03-01 to 2022-02-16 | 11,806 Common Stock | (F2) Represents first vesting date. Option vested over four years from date of grant. |